EBS Technologies, a Hennigsdorf close to Berlin, Germany-based developer of a therapy for the treatment of visual field loss, raised €1.1m in financing.
The round, which is still open to additional investors, was led by Earlybird and High-Tech Gruenderfonds with participation from Prof. Dr. med. Jens Ellrich, former CMO at Sapiens, which is part of Medtronic now, and private investor Rainer Christine.
The company intends to use the funds to for faster market penetration, firstly in the USA.
Led by Ulf Pommerening, CEO, EBS Technologies develops software and hardware for medical stimulation therapies. The company has completed a clinical trial of the EBS therapy, an innovative non-invasive treatment option for patients with visual field loss. The treatment was introduced in the German market in 2014 and is available in selected German eye care clinics and therapy centers.
It is approved for the treatment of visual field loss in accordance with EU regulations as a medical device with a CE label.